Penn Medicine
Help | Search | Site Map | Contact   
faculty photo

Pablo Tebas, M.D.

Professor of Medicine at the Hospital of the University of Pennsylvania
Attending Physician, Hospital of the University of Pennsylvania
Director & Principal Investigator, AIDS Clinical Trial Unit (ACTU) research site, University of Pennsylvania
Investigator of the Vaccine Trials Network, University of Pennsylvania
Director, Developmental Core Center for AIDS research (CFAR), Perelman School of Medicine, University of Pennsylvania
Department: Medicine

Contact information
Academic Address: 502 Johnson Pavilion
Clinical Office: 4 Perelman Center for Advanced Medicine, 3600 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-349-8092
Fax: 215-349-8011
Universidad Autónoma de Madrid, Spain, 1985.
Post-Graduate Training
Intern in Medicine, Hospital Puerta de Hierro, Madrid, Spain, 1986-1987.
Resident in Medicine, Hospital Puerta de Hierro, Madrid, Spain, 1987-1991.
Fellowship, Infectious Diseases, Washington University in Saint Louis, Missouri, 1992-1995.
Spanish Board of Internal Medicine, 1992.
American Board of Internal Medicine, Internal Medicine, 2014.
American Board of Internal Medicine, Infectious Diseases, 2015.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

My research interests center around the study of the complications of HIV and its treatment, and currently in the evaluation of strategies for the cure of HIV infection.
I am the director and the PI of the AIDS clinical trial unit of the University of Pennsylvania.
I am one of the founding members of the HIV Reservoirs and Viral Eradication (Cure) Transformative Science Group (TSG) of the AIDS clinical trial group. In addition to my ACTG work, I am involved (as PI of the clinical project) in several early phase trials of new compounds developed in conjunction with the NIH in several IPCP grants, including a Phase I study evaluating the antiviral activity of aprepitant (an NK-1R antagonist that down-regulates the expression of CCR5), a phase I study evaluating the immunogenicity of a therapeutic DNA vaccine administered by intramuscular electroporation in collaboration with David Weiner and several gene therapy studies evaluating the therapeutic use of lentiviral vectors in the management of HIV infection (including the use of VIRxSYS 496 –antisense approach-, the first in humans Sangamo’s zinc finger nuclease for CCR5 edition, in collaboration with Dr. Carl June.

Description of Clinical Expertise

My clinical interest focus on the treatment of HIV infection and associated infections like hepatitis C. I have also a particular interest in the clinical manifestations and treatment of atypical mycobacterial infections. I also attend every year in the general infectious disease service of the hospital of University of Pennsylvania

Selected Publications

Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E: Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet 36(17): 32299-7, Sep 2017.

Herati RS, Muselman A, Vella L, Bengsch B, Parkhouse K, Del Alcazar D, Kotzin J, Doyle SA, Tebas P, Hensley SE, Su LF, Schmader KE, Wherry EJ: Successive annual influenza vaccination induces a recurrent oligoclonotypic memory response in circulating T follicular helper cells. Sci Immunol 2(8), Aug 2017.

Koenig HC, Mounzer K, Daughtridge GW, Sloan CE, Lalley-Chareczko L, Moorthy GS, Conyngham SC, Zuppa AF, Montaner LJ, Tebas P: Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis. HIV Med 18(6): 412-418, June 2017.

Beigel, J. H., Tebas, P., Elie-Turenne, M. C., Bajwa, E., Bell, T. E., Cairns, C. B., Shoham, S., Deville, J. G., Feucht, E., Feinberg, J., Luke, T., Raviprakash, K., Danko, J., O'Neil, D., Metcalf, J. A., King, K., Burgess, T. H., Aga, E., Lane, H. C., Hughes, M. D., Davey, R. T., I. R. C. Study Team: Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respir Med 5(6): 500-511, June 2017.

Drechsler, H., Ayers, C., Cutrell, J., Maalouf, N., Tebas, P., Bedimo, R.: Current use of statins reduces risk of HIV rebound on suppressive HAART. PLoS One 12(3): e0172175, March 2017.

Huhn GD, Tebas P, Gallant J, Wilkin T, Cheng A, Yan M, Zhong L, Callebaut C, Custodio JM, Fordyce MW, Das M, McCallister S: A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults. J Acquir Immune Defic Syndr 74(2): 193-200, Feb 2017.

O'Brien MP, Hunt PW, Kitch DW, Klingman K, Stein JH, Funderburg NT, Berger J S, Tebas P, Clagett B, Moisi D, Utay NS, Aweeka F, Aberg JA: A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy. Open Forum Infect Dis 4(1): ofw278, Jan 2017.

Bar, K. J., Sneller, M. C., Harrison, L. J., Justement, J. S., Overton, E. T., Petrone, M. E., Salantes, D. B., Seamon, C. A., Scheinfeld, B., Kwan, R. W., Learn, G. H., Proschan, M. A., Kreider, E. F., Blazkova, J., Bardsley, M., Refsland, E. W., Messer, M., Clarridge, K. E., Tustin, N. B., Madden, P. J., Oden, K., O'Dell, S. J., Jarocki, B., Shiakolas, A. R., Tressler, R. L., Doria-Rose, N. A., Bailer, R. T., Ledgerwood, J. E., Capparelli, E. V., Lynch, R. M., Graham, B. S., Moir, S., Koup, R. A., Mascola, J. R., Hoxie, J. A., Fauci, A. S., Tebas, P., Chun, T. W.: Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. N Engl J Med 375(21): 2037-2050, November 2016.

Post Frank A, Tebas Pablo, Clarke Amanda, Cotte Laurent, Short William, Abram Michael E, Jiang Shuping, Cheng Andrew, Das Moupali, Fordyce Marshall W: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. Journal of acquired immune deficiency syndromes (1999) Sep 2016.

Lederman MM, Cannon PM, Currier JS, June CH, Kiem HP, Kuritzkes DR, Lewin SR, Margolis DM, McCune JM, Mellors JW, Schacker TW, Sekaly RP, Tebas P, Walker BD, Douek DC: A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"? Pathogens & immunity 1(1): 154-164, Sept 2016.

back to top
Last updated: 11/02/2017
The Trustees of the University of Pennsylvania
© The Trustees of the University of Pennsylvania. Site best viewed with Mozilla, NN, IE, or Safari.
SOM Home International Programs Penn Alumni Clinical Trials Centers and Institutes Departments Faculty Research Education Administration